1.

Baseline characteristics (N=326)

Characteristics	n	%	Median (range)
ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderate differentiated; PD, poorly differentiated; SRC, signet ring cell carcinoma; LN, lymph node; UNL, upper normal limit; WBC, white blood cells; ALP, alkaline phosphatase; qPCR, quantitative polymerase chain reaction; gCN, gene copy number; *, hemoglobin ≤12 g/dL for women and ≤13 g/dL for men; **, initial complete blood count, alkaline phosphatase and bilirubin levels, and scores from the Asan Medical Center prognostic model were not available in 9 patients (2.8%); ***, albumin level was not available in 11 patients (3.4%).
Male	225	69.0
Age (≥65 years)	83	25.5	58 (23−85)
ECOG PS
0−1	287	88.0
2−3	39	12.0
Borrmann type
I	17	5.2
II	71	21.8
III	177	54.3
IV	50	15.3
Early gastric cancer	10	3.1
Not available	1	0.3
Histology
WD/MD	117	35.9
PD/SRC/mucinous	203	62.3
Others	6	1.8
No gastrectomy	211	64.7
Disease status
Initially metastatic	215	66.0
Recurred	98	30.1
Locally advanced	13	4.0
Metastatic organ
Peritoneum	157	48.2
Liver	94	28.8
Lung	20	6.1
Intraabdominal distant LN	154	47.2
Extraabdominal distant LN	31	9.5
Bone	27	8.3
Hemoglobin ≤UNL*,**	222	68.1	11.7 (6.7−17.4)
WBC≥10,000/mm3**	47	14.4	6,900 (2,200−48,700)
Platelet ≤150×103/mm3**	38	11.7	265 (14−630)×103
Albumin <3.3 g/dL***	104	31.9	3.6 (1.7−5.3)
ALP>120 IU/L**	70	21.5	79 (29−1,294)
Total bilirubin >1.2 mg/dL**	28	8.6	0.6 (0.2−6)
Asan medical center prognostic model**
Good (0−1)	154	47.2
Moderate (2−3)	111	34.0
Poor (≥4)	52	16.0
MET qPCR >5 gCN	21	6.4	2.68 (0.73−513.04)